Publication of supplement to prospectus
Oncology Venture Sweden AB (”Oncology Venture”) hereby publish a supplement to the prospectus due to the press release with the headline “Oncology Venture will execute license to multi TKI phase 3 compound” that the company published on January 15th, 2018, which was published after the approval of the company’s prospectus by the Swedish Financial Supervisory Authority prior to Oncology Venture’s rights issue with subscription period on January 11th – January 25th, 2018. The supplement to the prospectus is available on the company’s (www.oncologyventure.com), Sedermera Fondkommission’s (www.